Introduction
============

Prostate cancer (PCa) is the second most commonly diagnosed invasive cancer worldwide and the fifth most frequent cause of cancer deaths in men^[@r1]^. The clinical course of PCa is heterogeneous: Some cases are indolent and exhibit slow growth that is limited to the organ and do not progress if left untreated, whereas other cases can progress to lethal metastatic disease^[@r2],[@r3]^. Clinical and pathological features such as Gleason score, tumor stage, and levels of prostate specific antigen (PSA) in blood can be used to determine aggressiveness of PCa^[@r4],[@r5]^. For histological assessment of PCa, in 2014 the International Society of Urological Pathology (ISUP) recommended that a modified Gleason score be used as a new prognostic grading system. This modified grading system (ISUP 2014) was a better predictor of both biochemical and clinical recurrence compared to the Gleason scoring system^[@r6]^. Meanwhile, the PSA test is commonly performed to screen for PCa, but this test has both weak sensitivity and specificity that can result in overdiagnosis and overtreatment. Therefore, new molecular biomarkers are needed for the diagnosis and prognosis of PCa as well as for improved identification of potentially indolent PCa^[@r7]^.

Epigenetic and genetic changes are both common features of PCa. DNA methylation is an epigenetic change that regulates the differential expression of genes and involves covalent binding of a methyl group to the dinucleotide cytosine guanine at the C-5 position of the cytosine ring. Methylation is mainly regulated by DNA methyltransferases (DNMTs). Hypermethylation of promoter CpG islands can silence tumor suppressor genes early during tumorigenesis, while global hypomethylation occurs later in the course of PCa^[@r7],[@r8]^. A wide range of tumor suppressor genes have been reported to be epigenetically silenced by promoter DNA hypermethylation in PCa and these genes mainly regulate cell proliferation, DNA repair, apoptosis, tissue invasion and metastasis^[@r9]^. The gene encoding glutathione S-transferase-p1 (GSTP1) has been extensively studied for PCa, and its expression is inactivated in \>90% of cases with PCa due to aberrant DNA methylation of CpG islands in the promoter^[@r2],[@r10],[@r11]^. These methylation events seem to be involved during an early stage of prostatic carcinogenesis. Compared with PSA, serum levels of GSTP1 are more specific for PCa, since GSTP1 is not typically expressed in normal prostate tissue^[@r11]^. Therefore, GSTP1 could serve as an epigenetic biomarker for detection of PCa^[@r7],[@r12]^. Other genes that are frequently silenced by promoter DNA hypermethylation in PCa include APC, PTSG2, E-cadherin, RARb27. Since DNA methylation alterations are stable and easily measurable, differences in methylation patterns between normal and tumor cells could have potential application for the detection of tumor cells in biopsy specimens or body fluids^[@r7],[@r13],[@r14]^.

The aim of this study was to investigate the methylation status of Ras-associated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), phosphatase with tensin homology (PTEN) and suppressor of cytokine signaling 3 (SOCS3) in blood from PCa patients and to evaluate the clinical utility of these genes as noninvasive, blood-based epigenetic biomarkers that could be used for PCa diagnosis.

Materials and Methods
=====================

Study population and sample collection
--------------------------------------

A total of 41 consecutive patients who were currently diagnosed with PCa but had not undergone radical prostatectomy or other therapies and 10 healthy control patients treated at the Urology Department of Istanbul Medeniyet University, Göztepe Training and Research Hospital were enrolled. The ethics committee at the Göztepe Training and Research Hospital approved the study protocol, and all enrolled patients provided signed informed consent for participation in the study. Peripheral blood samples (5 ml) were obtained from each participant and stored at -20°C until analysis.

DNA isolation
-------------

DNA was isolated from all samples using a Qiagen QIAmp DNA mini kit (Qiagen CA, USA). Briefly, 20 μL proteinase K and 200 μL lysis buffer were added to 200 μL blood samples. After incubation for 10 minutes at 56°C, 200 μL ethanol was added. The mixture was transferred to QIAmp spin columns and centrifuged for 1 min at 8,000 rpm. The centrifugation was repeated several times after addition of related wash buffers and the purified DNA was eluted in 100 μL Elution Buffer included in the kit. Concentrations of the isolated genomic DNA samples were measured using a NanodropTM spectrophotometer (Multiskan Go, Thermo Scientific, USA) and expressed as nanograms per microliter.

Bisulfite modification of DNA samples
-------------------------------------

Isolated genomic DNA samples were subjected to bisulfite deamination reactions using a Qiagen EpiTect Bisulfite kit (Qiagen, CA, USA) according to the manufacturer's instructions. Briefly, 500 ng DNA was mixed in PCR tubes with 85 μL bisulfite mix solution and 35 μL DNA preservation buffer in a 200 μL reaction. Samples were incubated in the thermal cycler device (Bio-Rad, USA) for 5 hours using the following reaction sequence: 95°C for 5 min followed by 25 min at 60°C, 5 minutes at 95°C, 85 min at 60°C, 5 min at 95°C and 175 min at 60°C. Samples were then transferred to Epitect spin columns before related buffers were added and the samples were centrifuged. Finally, the bisulfite-treated DNA samples were purified in 20 μL elution buffer.

PyroMark PCR
------------

PCR reactions were conducted using a Qiagen PyroMark PCR kit (Qiagen, CA, USA). Briefly, 12.5 μL master mix, 2.5 μL coral red, 5 pmol of each primer, 7 μL water, and 2 μL sample were mixed for each reaction and run under the following thermal cycling conditions: 95°C for 15 min, followed by 45 cycles of 30 sec at 94°C, 30 sec at the optimized primer-specific annealing temperature, and 30 sec at 72°C, followed by a final extension step for 10 min at 72°C. Amplification of the correct DNA products was confirmed by electrophoresis on a 2% low melting point agarose gel. Positive and negative controls were used for PyroMark PCR and pyrosequencing applications.

PyroMark CpG Sequencing Analysis
--------------------------------

Quality-controlled PCR products were subjected to methylation analysis using PyroMark CpG assay sequencing (Qiagen, US). Briefly, CpG sequencing was completed in three steps: (1) immobilization of PCR products on Streptavidin-Sepharose beads according to the manufacturer's protocol; (2) PCR-amplified DNA fragments were decomposed and transferred into a PyroMark Q24 plate using the Pyromark Workstation; (3) DNA was bound to sequence primers to initiate sequencing. For sequencing, Sepharose beads were mixed with 2 μL streptavidin, 40 μL binding buffer and 28 μL ultradistilled water and combined with 10 μL of PCR product from each sample in well-plates, which were incubated for 10 min at room temperature with shaking. Next, the mixture was transferred to a PyroMark Q24 plate wells with 2.5 μL/sample primary sequence, and 22.5 μL/sample Annealing Buffer/well. The PyroMark Workstation was prepared using 50 ml 70% ethanol, 40 ml denaturation solution, 50 ml wash buffer, and 50 and 70 ml ultra-distilled water. The plates were then transferred from the shaker to the Workstation. All PCR Sepharose-product complexes were subjected to vacuum filtration and sequentially washed with ethanol, denaturation solution and wash buffer for 10, 10 and 15 sec, respectively. The vacuum was applied for a further 2 min and then turned off to allow transfer of the complexes to the sequence mixture in the PyroMark Q24 plate. The vacuum filters were washed extensively in the workstation to avoid contamination of subsequent samples.

The PyroMark Q24 plates were placed into the Pyromark Sequencer and sequencing reactions were carried out using appropriate cartridges containing relevant enzyme, substrate and adenine, cytosine, guanine, and thymine. Sequencing reactions were run on the PyroMark Q24 sequencer and methylation analyses were done using PyroMark Q24 Analysis software version 2.0.6. The presence of a C nucleotide instead of T (at position Y) was interpreted as methylation, and methylation values are expressed as percentages.

aStatistical analysis
---------------------

Statistical analyses were performed using SPSS software version 22.0. In addition to descritive statistical values (mean, standard deviation), Student's t test was used to evaluate patient characteristics. Methylation levels were compared by Pearson test. A P value of \<0.05 was accepted as significant.

Results
=======

Study Population
----------------

In this prospective study, 21 localized and 20 locally advanced PCa were enrolled. The control group included 10 healthy age-matched men (mean age 69.9±5) who had no evidence of PCa. The mean age of the PCa patients was 70.7±6.5 years and the mean PSA level was 21.7±29 ng/ ml in the PCa, and 2.1±0.8 ng/ml in the control group. Clinical data was extracted from patient records. Patient characteristics are summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Baseline characteristics and correlation of promoter methylation levels for RASSF1A, MGMT, PTEN and SOCS3 in the study population.

                        Prostate cancer (n:41)   Control (n:10)   P-value
  --------------------- ------------------------ ---------------- ----------
  Age (years)           70.7±6.5                 69.9±5           0.66^a^
  Mean±SD                                                         
  PSA Level (ng/ml)     21.7±29                  2.1±0.8          0.002^a^
  Mean±SD                                                         
  Prostat Volume (ml)   41.6±19.1                42.3±19.4        0.92^a^
  Mean±SD                                                         
  BMI (kg/m^[@r2]^)     26.6±3.2                 25.9±1.8         0.32^a^
  Mean±SD                                                         
  RASSF1A (%)           17.1                     15.6             0.30^b^
  MGMT (%)              7.1                      7.3              0.82^b^
  PTEN (%)              11.1                     10.8             0.82^b^
  SOCS3 (%)             2.25                     2.23             0.95^b^

^a^*Student t test*

^b^*Pearson correlation*

###### 

Patient characteristics and correlation of promoter methylation levels for RASSF1, MGMT, PTEN, and SOCS3 in localized and locally advanced PCa patient groups.

                              Localized Prostate Cancer (n:21)   Locally Advanced Prostate Cancer (n:20)   P-value
  --------------------------- ---------------------------------- ----------------------------------------- -----------
  Age (years) Mean±SD         70±6.8                             71.4±6.3                                  0.38^a^
  BMI (kg/m^[@r2]^) Mean±SD   26±35                              272±29                                    0.65^a^
  PSA (ng/ml) Mean±SD         17.4±4.3                           16.8±3.8                                  0.45^a^
  Family history of any       10 (47.6%)                         14 (70%)                                  0.14^a^
  type of cancer                                                                                           
  Family history of PCa       5 (23.8%)                          5 (25%)                                   0.92^a^
  Smoking                     14 (66.7%)                         12 (60%)                                  0.65^a^
  ISUP Grade n (%)                                                                                         
                              9 (43%)                            1 (5%)                                    0.001^a^
                              4 (19%)                            5 (25%)                                   
                              6 (28%)                            1 (5%)                                    
                              2 (10%)                            8 (40%)                                   
                              0 (0%)                             5 (25%)                                   
  RASSF1 (%)                  17.4                               16.8                                      0\. 45^b^
  MGMT (%)                    7.02                               7.5                                       0.49^b^
  PTEN (%)                    12.2                               10                                        0.10^b^
  SOCS3 (%)                   2.5                                3.8                                       0.03^b^

^a^*Student t test*

^b^*Pearson correlation*

Promoter Methylation of RASSF1A, MGMT, PTEN and SOCS3
-----------------------------------------------------

Pyrosequencing was performed to map methylated CpG dinucleotides around bp 173, 253, 153 and 172 in RASSF1A, MGMT, PTEN and SOCS3 gene promoters, respectively ([Table 3](#T3){ref-type="table"}). Little to no difference in methylation levels was detected between the patient and control groups for RASSF1A, MGMT, PTEN, and SOCS3 promoters ([Table 1](#T1){ref-type="table"}). For promoter methylation levels of RASSF1A, MGMT, and PTEN, the sequencing results confirmed that there was no significant difference between the two patient groups and between the PCa and control groups. However, for the SOCS3 promoter, the methylation levels were significantly higher in patients having locally advanced PCa relative to those with localized PCa (p\<0.05) ([Table 2](#T2){ref-type="table"}).

###### 

Pyrosequencing primers (Amplification and Sequencing, 5' biotinylation).

  Primer Designation   Primer Sequence (5' ⊠ 3')      Orientation (Forw/Rev)   Annealing Temp (°C)   Thermo-cycles   Product Size (bp)
  -------------------- ------------------------------ ------------------------ --------------------- --------------- -------------------
  RASSF1A              AGTTTGGATTTTGGGGGAGG           F                        62                    45              173
                       CAACTCAATAAACTCAAACTCCCC       R                                                              
                       GTTTTGTGGTTT                   Seq\*                                                          
  MGMT                                                                                                               
                       GGTGATTGTAGTTTTTGG A           F                        58                    45              253
                       TCCTATCACAAAAATAATCC           R                                                              
                       GGTATTAGGAGGGGAGAGATT          Seq\*                                                          
                       GGTTTTTTTTGTAGGATGGAAATGGT     F                        61                    45              153
  PTEN                 CCCAAAAAACACCTATCTAAATAAACT    R                                                              
                       AAATGGTTTTGGATTT               Seq\*                                                          
                       TTGGAATTTGTTGTAGGTGAT          F                        60                    45              172
  SOCS3                ACCTTCTTATAATATTTAATCACTACTC   R                                                              
                       GGGGGTTTTTGATTAG               Seq\*                                                          

Seq\*: Sequencing primer

Discussion
==========

PCa is an important public health concern, particularly as the global population ages^[@r14]^. During early-stage PCa, patients exhibit few or no specific symptoms, and early detection of PCa is related to better outcomes^[@r8]^. PSA screening is currently the primary method used for early diagnosis of PCa. However, PSA testing does not discriminate between benign and malignant prostate disease, or between indolent and clinically significant PCa. Therefore, robust and reliable markers are needed to screen, diagnose, and monitor PCa neoplasms^[@r14],[@r15]^. DNA methylation represents a common, consistent event that may occur early in carcinogenesis and thus it is an attractive biomarker for PCa detection^[@r16]^. In this study, we determined the promoter methylation of four tumor suppressor genes, RASSF1A, MGMT, PTEN, and SOCS3, to identify DNA methylation markers that would be suitable for noninvasive diagnostic testing of blood samples from patients having localized and locally advanced PCa. DNA methylation levels were assessed using pyrosequencing, a high-throughput, quantitative method that can detect differences in DNA methylation with high sensitivity.

Examination of pyrosequencing results for RASSF1A showed that the average methylation level for all PCa patients in this study was higher than that of the control group (17.1% vs. 15.6%), but this difference was not statistically significant. No significant difference was also seen in RASSF1A promoter methylation levels between clinically localized and locally advanced PCa patients (17.4% vs. 16.8%). RASSF1A is a putative tumor suppressor gene located at 3p21.3 that is functionally associated with cell cycle control, microtubule stabilization, cellular adhesion, motility, and apoptosis. Epigenetic silencing of RASSF1A by hypermethylation of CpG islands within the promoter region has been observed in various cancer types, including PCa. Although multiple studies have investigated RASSF1A promoter methylation and its association with PCa, no consistent conclusion has been obtained, perhaps due to the diversity of sample materials and testing methods as well as small sample sizes^[@r17]^.

For the DNA repair gene MGMT, methylation was detected in 7.1% and 7.3% of patients in the PCa group and control group, respectively. We observed little to no difference in MGMT methylation levels between samples obtained from localized and locally advanced cases with PCa (7.02% vs. 7.2%, respectively, p\>0.05). Our findings were consistent with those of Brait et al.^[@r8]^, who also didn't observe any statistically significant association in DNA methylation of MGMT in either serum or tumor tissues harvested from PCa patients. Other studies also reported no significant differences in MGMT promoter methylation in PCa cases compared to healthy controls^[@r18]-[@r20]^. However, as reported in a study by Kang et al.^[@r21]^, 75.7% of tissue samples obtained from PCa patients did exhibit MGMT methylation. The reason why the results of this study differ from the others could be because of heterogeneity of prostate tumors.

PTEN is mutated or deleted in PCa as well as in several other tumors. As a tumor suppressor gene, PTEN is involved in PI3-kinase pathway regulation. PTEN family enzymes are involved in cell growth, proliferation, differentiation, and apoptosis^[@r22]^. As with RASSF1A and MGMT, we did not detect any significant change in PTEN methylation levels between the control and PCa patient groups or between the two PCa patient groups (p\>0.05). Whang et al.^[@r23]^ suggested that PTEN is inactivated by promoter methylation in advanced PCa. Furthermore, Geybels et al.^[@r24]^ reported that deletion or mutation of PTEN may enhance tumor progression by inducing DNA methylation in patients with PCa recurrence. Notably, our patient population did not contain any cases of PCa recurrence, which could explain the reason why any changes in PTEN promoter methylation were not observed.

We did detect a statistically significant increase in SOCS3 promoter methylation levels in patients who had locally advanced PCa compared to those who had localized PCa (2.2% and 2.3%, respectively; p\<0.05). Meanwhile, there was no significant difference in SOCS3 promoter methylation levels between the control and the PCa patient group. SOCS3 is a negative regulator of the IL6/ JAK/STAT3 pathway that is linked to development of PCa and castration resistance. Upon activation of the IL6/JAK/STAT3 signaling cascade, STAT3 was shown to enhance the activation of androgen receptor and contribute to progression to castration resistance in PCa. Increased STAT3 levels are observed both in primary and metastatic PCa. As a STAT3 inhibitor, SOCS3 expression is commonly inactivated by promoter hypermethylation in a wide range of tumor types, including PCa. Handle et al.^[@r25]^ and Pierconti et al.^[@r26]^ proposed that SOCS3 promoter methylation may be a potential biomarker to identify an aggressive subset of PCa tumors. They also reported that SOCS3 methylation is correlated with medium and high grade Gleason scores, and poor clinical results. Similarly, our data suggested that hypermethylation of the SOCS3 promoter was more frequent in blood samples obtained from patients with locally advanced PCa and was significantly associated with high ISUP grade (Grades 4 and 5; [Table 2](#T2){ref-type="table"}). One limitation of our study is the small number subjects, both with PCa and healthy controls. As such, our findings require validation in a larger sample.

Conclusion
==========

Our findings suggest that SOCS3 promoter methylation has a potential for use as a noninvasive epigenetic biomarker for the diagnosis of locally advanced PCa. At the diagnostic stage of PCa, epigenetic markers as well as clinicopathological features are valuable and could be determinants for selection of effective treatments. Further studies will be needed to assess the possible clinical benefit of SOCS3 promoter methylation as an epigenetic diagnostic biomarker of PCa.
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